Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

On behalf of all authors, we thank Dr. Kearney for the comment on our article.1 The reported “90% reduction in gadolinium-enhancing lesions,” referred to by Dr. Kearny, should only be considered inflated if our article claimed these results are to be compared to results of active comparator studies such as the alemtuzumab vs interferon study (our study was not an active comparator study).2 With respect to “time is brain,” we fully agree and the same trial design would not be currently pursued. While only published in 2018, the results of the MIRROR study were first presented over 4 years prior, with design and execution that predated that by approximately 2 additional years.